Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555527 | 0.88 | STS (0.60) | GPR119STSTGFBR1 | |
| SCHEMBL4777938 | 0.87 | GPR119 (0.54) | GPR119STSNPSR1 | |
| SCHEMBL13932906 | 0.87 | CACNA1B (0.66) | GPR119STSCACNA1BTGFBR1 | |
| SCHEMBL2960832 | 0.83 | STS (0.52) | GPR119STSMEN1KMT2ANPSR1 | |
| SCHEMBL18418300 | 0.82 | MGLL (0.58) | GPR119 | |
| SCHEMBL29222206 | 0.81 | ALDH1A1 (0.50) | GPR119KDM4EUSP30 | |
| SCHEMBL24762022 | 0.81 | GPR119 (0.48) | GPR119STSNPSR1 | |
| SCHEMBL10177808 | 0.80 | GPR119 (0.51) | GPR119MEN1KMT2A | |
| SCHEMBL652408 | 0.80 | MEN1 (0.57) | GPR119STSMEN1KMT2AKDM4E | |
| SCHEMBL4131432 | 0.80 | STS (0.57) | GPR119STSMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | HALE JEFFREY J (US) | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094989-A1 | Pyrrolidine modulators of CCR5 chemokine receptor activity | CCR5, CCR1, CXCR1 | GPR119 502/4885STS 4206/4885CACNA1B 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.